Somatropin Shows Long-Term Safety and Effectiveness in Pediatric Patients with growth hormone deficiency: Study

A recent study found Omnitrope® (somatropin) to be effective and safe in pediatric patients over long term. The findings from the PATRO Children study were published in the journal of Drug Design, Development and Therapy.

Amidst the ongoing concerns over the safety and effectiveness of pediatric treatments, Omnitrope® (somatropin) which is a biosimilar recombinant human growth hormone (rhGH) showed positive outcomes. The latest data from the PATRO Children study highlights its remarkable performance in real-world clinical settings.

The PATRO Children study was conducted to monitor the long-term safety and efficacy of Omnitrope® and enrolled a substantial cohort of 7359 pediatric patients, majority of whom were treatment-naïve. The results underline the well-tolerated nature of this treatment with a notable 86.0% of patients being new to therapy at the onset of the study.

Growth hormone deficiency was found to be the predominant indication for treatment, that was followed closely by patients born small for gestational age (SGA). Throughout the study duration, the patients expressed a sustained catch-up growth with the standard deviation scores (SDS) of height significantly improving over time.